

# Toll Like Receptor 8 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/T372E5610BF0EN.html>

Date: January 2020

Pages: 84

Price: US\$ 3,500.00 (Single User License)

ID: T372E5610BF0EN

## Abstracts

Toll Like Receptor 8 - Pipeline Review, H1 2020

### SUMMARY

Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.

Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 8 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Melanoma, Solid Tumor, Autoimmune Disorders, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Melanoma, Systemic Lupus Erythematosus, Adenoid Cystic Carcinoma (ACC), Arthritis, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Hepatitis B, Hepatocellular Carcinoma, Inflammation, Leukemia, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Osteoarthritis, Peritoneal Cancer, Rabies, Renal Cell Carcinoma, Rheumatoid Arthritis, Sarcomas, Sicca Syndrome (Sjogren), Squamous Cell Carcinoma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Triple-Negative Breast Cancer (TNBC).

The latest report Toll Like Receptor 8 - Pipeline Review, H1 2020, outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted

therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)

The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects

The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Toll Like Receptor 8 (CD288

or TLR8) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Toll Like Receptor 8 (CD288 or TLR8) - Overview

Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics  
Development

Altimune Inc

Ascendis Pharma A/S

BioNTech SE

Bolt Biotherapeutics Inc

Bristol-Myers Squibb Co

Curebiotech Inc

Curevac AG

Dynavax Technologies Corp

Eisai Co Ltd

Galderma SA

Gilead Sciences Inc

Ingenovax LLC

Janus Biotherapeutics Inc

Nektar Therapeutics

Seven and Eight Biopharmaceuticals Corp

Shanghai De Novo Pharmatech Co Ltd

Silverback Therapeutics Inc

Vaccex Inc

Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles

ALT-702 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BDB-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUCPT-8m - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-8102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DN-1508052 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-6742 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INGMM-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JB-6121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugates to Agonize TLR7 and TLR8 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

motolimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products

Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones

Featured News & Press Releases

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Altimune Inc, H1 2020

Pipeline by Ascendis Pharma A/S, H1 2020

Pipeline by BioNTech SE, H1 2020

Pipeline by Bolt Biotherapeutics Inc, H1 2020

Pipeline by Bristol-Myers Squibb Co, H1 2020

Pipeline by Curebiotech Inc, H1 2020

Pipeline by Curevac AG, H1 2020

Pipeline by Dynavax Technologies Corp, H1 2020

Pipeline by Eisai Co Ltd, H1 2020

Pipeline by Galderma SA, H1 2020

Pipeline by Gilead Sciences Inc, H1 2020

Pipeline by Ingenovax LLC, H1 2020

Pipeline by Janus Biotherapeutics Inc, H1 2020

Pipeline by Nektar Therapeutics, H1 2020

Pipeline by Seven and Eight Biopharmaceuticals Corp, H1 2020

Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020

Pipeline by Silverback Therapeutics Inc, H1 2020

Pipeline by Vaccex Inc, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Top 10 Indications, H1 2020  
Number of Products by Mechanism of Actions, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Altimune Inc  
Ascendis Pharma A/S  
BioNTech SE  
Bolt Biotherapeutics Inc  
Bristol-Myers Squibb Co  
Curebiotech Inc  
Curevac AG  
Dynavax Technologies Corp  
Eisai Co Ltd  
Galderma SA  
Gilead Sciences Inc  
IngenoVax LLC  
Janus Biotherapeutics Inc  
Nektar Therapeutics  
Seven and Eight Biopharmaceuticals Corp  
Shanghai De Novo Pharmatech Co Ltd  
Silverback Therapeutics Inc  
Vaccex Inc



## I would like to order

Product name: Toll Like Receptor 8 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/T372E5610BF0EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T372E5610BF0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970